VCEL
Vericel Corp
NASDAQ · Healthcare · Biotechnology · US
$40.37
+0.60%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$40.36
From 52W high−16.44%
Volume334216.00
Market cap$2.07B
P/E (TTM)84.1x
P/S (TTM)6.7x
Div yield—
Key dataOct 19, 2026
Open
$40.36
From 52W high
−16.44%
Volume
334216.00
Market cap
$2.07B
ValuationView details →
P/E (Fwd)
51.0x
EV/EBITDA
51.5x
P/E (TTM)
84.1x
RSI (14)
51.1
MomentumView details →
1D Return
+0.60%
YTD Return
+12.75%
SummaryUpdated Jun 1, 2026
Vericel Corporation (NASDAQ:VCEL) is a commercial-stage biopharmaceutical company founded in 1989 and headquartered in Cambridge, Massachusetts. Originally incorporated as Aastrom Biosciences, the company went public in 1997 and later rebranded to Vericel Corporation. The company specializes in developing, manufacturing, and commercializing autologous cellular therapies, which are treatments that use a patient's own cells to repair damaged tissue. Vericel has successfully transitioned from a research-focused organization to a profitable commercial enterprise, with two FDA-approved products generating revenue in specialized medical markets.
Similar companies
Latest newsMore news →
Bank of America Corp DE increased its stake in Vericel Corporation by 19.7% during the quarter, acquiring an additional 180,761 shares, according to its SEC disclosure.66d agoVericel Corporation's Board of Directors authorized a $200 million share repurchase program.82d agoVericel Corporation reported financial results for the second quarter ended June 30, 2026, with total net revenue of $77.5 million, net income of $2.2 million, and free cash flow of $14.3 million.82d ago